175 related articles for article (PubMed ID: 20637884)
1. Dysglycemia following glucocorticoid therapy for acute graft-versus-host disease adversely affects transplantation outcomes.
Pidala J; Kim J; Kharfan-Dabaja MA; Nishihori T; Field T; Perkins J; Perez L; Fernandez H; Anasetti C
Biol Blood Marrow Transplant; 2011 Feb; 17(2):239-48. PubMed ID: 20637884
[TBL] [Abstract][Full Text] [Related]
2. Early Hyperglycemia after Initiation of Glucocorticoid Therapy Predicts Adverse Outcome in Patients with Acute Graft-versus-Host Disease.
Stauber MN; Aberer F; Oulhaj A; Mader JK; Zebisch A; Pieber TR; Neumeister P; Greinix HT; Sill H; Sourij H; Wölfler A
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1186-1192. PubMed ID: 28285080
[TBL] [Abstract][Full Text] [Related]
3. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
[TBL] [Abstract][Full Text] [Related]
4. Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level.
Fingrut W; Law A; Lam W; Michelis FV; Viswabandya A; Lipton JH; Kumar R; Mattsson J; Kim DDH
Ann Hematol; 2021 Mar; 100(3):789-798. PubMed ID: 33415423
[TBL] [Abstract][Full Text] [Related]
5. CD4+ T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation.
de Koning C; Prockop S; van Roessel I; Kernan N; Klein E; Langenhorst J; Szanto C; Belderbos M; Bierings M; Boulad F; Bresters D; Cancio M; Curran K; Kollen W; O'Reilly R; Scaradavou A; Spitzer B; Versluijs B; Huitema A; Lindemans C; Nierkens S; Boelens JJ
Blood; 2021 Feb; 137(6):848-855. PubMed ID: 33150379
[TBL] [Abstract][Full Text] [Related]
6. Differential Association between Blood Glucose Levels and Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation Based on Presence or Absence of Preexisting Diabetes.
Rashid N; Gooley T; Boeckh M; Oshima MU; Chao JH; Hirsch IB; Mielcarek M
Transplant Cell Ther; 2024 Apr; 30(4):417.e1-417.e9. PubMed ID: 38242443
[TBL] [Abstract][Full Text] [Related]
7. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease.
Hoda D; Pidala J; Salgado-Vila N; Kim J; Perkins J; Bookout R; Field T; Perez L; Ayala E; Ochoa-Bayona JL; Raychaudhuri J; Alsina M; Greene J; Janssen W; Fernandez HF; Anasetti C; Kharfan-Dabaja MA
Bone Marrow Transplant; 2010 Aug; 45(8):1347-51. PubMed ID: 19966849
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience.
Yucebay F; Matthews C; Puto M; Li J; William B; Jaglowski SM; Penza SL; Vasu S; Benson DM; Andritsos LA; Devine SM; Efebera YA; Roddy JVF
Leuk Lymphoma; 2019 Sep; 60(9):2223-2229. PubMed ID: 30764681
[TBL] [Abstract][Full Text] [Related]
9. Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis.
Snyder DS; Palmer J; Gaal K; Stein AS; Pullarkat V; Sahebi F; Vora N; Nakamura R; Forman SJ
Biol Blood Marrow Transplant; 2010 Feb; 16(2):281-6. PubMed ID: 19786111
[TBL] [Abstract][Full Text] [Related]
10. The contribution of malglycemia to mortality among allogeneic hematopoietic cell transplant recipients.
Hammer MJ; Casper C; Gooley TA; O'Donnell PV; Boeckh M; Hirsch IB
Biol Blood Marrow Transplant; 2009 Mar; 15(3):344-51. PubMed ID: 19203725
[TBL] [Abstract][Full Text] [Related]
11. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
12. Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34
Scordo M; Shah GL; Kosuri S; Herrera DA; Cho C; Devlin SM; Maloy MA; Nieves J; Borrill T; Avecilla ST; Meagher RC; Carlow DC; O'Reilly RJ; Papadopoulos EB; Jakubowski AA; Koehne G; Gyurkocza B; Castro-Malaspina H; Tamari R; Perales MA; Giralt SA; Shaffer BC
Biol Blood Marrow Transplant; 2018 Jan; 24(1):133-141. PubMed ID: 28870777
[TBL] [Abstract][Full Text] [Related]
13. The utility of cognitive changes in identifying those with acute graft vs. host disease following allogeneic hematopoietic cell transplant.
Stratton J; Sylvia A; Hoodin F; Choi SW; Pawarode A; Giordani B; Votruba K
Clin Neuropsychol; 2020 Jul; 34(5):969-980. PubMed ID: 31619131
[No Abstract] [Full Text] [Related]
14. Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation.
Rezvani AR; Storer BE; Storb RF; Mielcarek M; Maloney DG; Sandmaier BM; Martin PJ; McDonald GB
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1594-601. PubMed ID: 21806949
[TBL] [Abstract][Full Text] [Related]
15. Low Counts of Plasmacytoid Dendritic Cells after Engraftment Are Associated with High Early Mortality after Allogeneic Stem Cell Transplantation.
Gonçalves MV; Yamamoto M; Kimura EY; Colturato VA; de Souza MP; Mauad M; Ikoma MV; Novis Y; Rocha V; Ginani VC; Wanderley de Oliveira Felix OM; Seber A; Kerbauy FR; Hamerschlak N; Orfao A; Rodrigues CA
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1223-9. PubMed ID: 25792371
[TBL] [Abstract][Full Text] [Related]
16. Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease.
Pidala J; Kim J; Roman-Diaz J; Shapiro J; Nishihori T; Bookout R; Anasetti C; Kharfan-Dabaja MA
Ann Transplant; 2010; 15(4):21-9. PubMed ID: 21183872
[TBL] [Abstract][Full Text] [Related]
17. [Anti-CD(25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic stem cell transplantation].
Tao T; Xue SL; Chen F; Xu Y; Ma X; Miao M; Tang XW; Wu DP
Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):324-329. PubMed ID: 29747286
[No Abstract] [Full Text] [Related]
18. Graft-versus-host disease treatment: predictors of survival.
Levine JE; Logan B; Wu J; Alousi AM; Ho V; Bolaños-Meade J; Weisdorf D;
Biol Blood Marrow Transplant; 2010 Dec; 16(12):1693-9. PubMed ID: 20541024
[TBL] [Abstract][Full Text] [Related]
19. Acute gastrointestinal graft-versus-host disease in pediatric patients: serum albumin on day 5 from initiation of therapy correlates with nonrelapse mortality and overall survival.
Goussetis E; Paisiou A; Kitra V; Peristeri I; Vessalas G; Stefanaki K; Panayotou I; Giamaiou K; Kontou E; Kitzoni M; Dimopoulou MN; Karkelis S; Kafritsa Y; Rapsomaniki E; Papassotiriou I; Tsirigotis P; Roma E; Graphakos S
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1058-66. PubMed ID: 21073975
[TBL] [Abstract][Full Text] [Related]
20. Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation.
Pasic I; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Mattsson J; Michelis FV
Ann Hematol; 2020 Jun; 99(6):1377-1387. PubMed ID: 32382774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
